Trial Profile
Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2022
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Antithymocyte globulin
- Indications Liver-kidney transplant rejection
- Focus Pharmacodynamics
- Acronyms TReg Kidney
- 26 Aug 2022 Status changed from suspended to discontinued.
- 03 Jun 2020 Planned End Date changed from 1 Nov 2019 to 1 Jan 2022.
- 03 Jun 2020 Planned primary completion date changed from 1 Nov 2019 to 1 Jan 2022.